1. Scrip
  2. >>COVID-19

China Still Leading Vaccines Race Despite Moderna Data, US 'Warp Speed' Plan?

Four In Phase I/II Vs Two From US

 
• By Brian Yang

The unveiling of US president Donald Trump’s 'Warp Speed’ plan to fast-track a coronavirus vaccine and the latest promising Phase I data from Moderna's candidate haven't seemed to swing China’s belief that it’s still leading the race.

China USA or United States trade and American tariffs conflict with two opposing trading partners as an economic import and exports dispute concept with 3D illustration elements
CHINA, US RACING TO HAVE FIRST CORONAVIRUS VACCINES ON THE MARKET • Source: Shutterstock

The US plan to have a coronavirus vaccine ready by the end of the year, unveiled on 15 May by President Donald Trump, has many wondering if the race to develop such a product is heating up considerably, given that on 18 May one of the leading developers, US firm Moderna Inc., disclosed positive preliminary results from a Phase I trial for its mRNA-based vaccine.

The recent developments are further stirring up a debate over whether the US is getting ahead of China, which started...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.